Global Organ-on-a-Chip Devices Market 2026 – 2035

The market size of the global organ-on-a-chip devices will be estimated at USD 134 million in 2025 and is expected to grow to between USD 179 million in 2026 and about USD 2409 million by 2035 with a current CAGR of 33.5% during the period of 2026 to 2035. The organ-on-a-chip devices market is witnessing the main driving force of the increasing demand for more precise and human-relevant preclinical models in drug discovery and development.

The use of traditional 2D cell cultures and animal models is often not able to accurately predict human toxicity and efficacy, resulting in high late-stage clinical failure rates and the corresponding increase in R&D costs. Fortunately, OoC devices are able to work over this gap by mimicking human organ physiology quite closely, that is to say, through the use of mechanical forces, microfluidic flow, and cell–cell interactions. This opens up the possibility of predicting drug safety and performance better and at an earlier stage. The strong desire of pharmaceutical and biotechnology companies to reduce attrition rates and development timelines is the major factor driving growth.

Market Highlight

• North America had a market share of 51% and was the market leader in the organ-on-a-chip devices market in 2025.

• The Asia Pacific is expected to grow at the highest CAGR during the years 2026-2035.

• By product, the liver-on-a-chip segment held the largest market share of over 35% in 2025.

• By end use, the pharmaceutical & biotechnology companies segment captures the largest market share of over 70% in 2025.

Significant Growth Factors

The organ-on-a-chip devices market trends present significant growth opportunities due to several factors:

• Rising Demand for Alternatives to Animal Testing: The increasing need for non-animal testing methods is leading to organ-on-a-chip devices becoming more popular as pharmaceutical and biotechnology industries containing more ethical, cost-effective, and human-relevant testing methods are looking for them. Traditional animal models result in long and costly drug-development processes that sometimes even mislead the researchers and cause drug attrition in clinical trials. Organ-on-a-chip devices mimic the human organ physiology by recreating the essential features such as tissue architecture, fluid flow, and biochemical signaling, which results in the studies not being dependent on animals and producing more predictive safety and efficacy data. At the same time, growing ethical issues, stricter regulations on the use of animals in research, and greater acceptance of non-animal testing methods by the regulatory authorities are all factors that are urging the pharmaceutical companies to switch to new methodologies that include OoC platforms. Consequently, the pressure for animal-free testing solutions is a major factor that is causing the widespread use of organ-on-a-chip technologies in various areas like drug discovery, toxicity testing, and safety assessment, thereby boosting the market growth.

• Broadening Applications Beyond Pharma: The increasing number of applications that go beyond pharmaceuticals is one of the main factors that are driving the organ-on-a-chip devices market thus the technology is widely accepted in different non-pharmaceutical industries that require reliable, human-relevant testing models. The pharmaceutical industry mainly uses OoC platforms for new drug development, safety testing, and toxicity testing, where use of cells from patients may help identify different therapy responses according to each individual. Moreover, the technology is also increasingly welcomed by the cosmetics and personal care industry in places where animal testing is either totally prohibited or very limited because, in such places, the use of OoC devices for testing and non-animal alternatives is both compliant and predictive. Furthermore, it is anticipated that high-throughput organ-on-chip technologies will be increasingly applied in chemical safety assessment, environmental toxicology, and food testing as regulators and manufacturers will be increasingly looking for advanced in vitro models that can determine human exposure risks more accurately. The ongoing and increasing diversification of use cases not only enlarges the market for organ-on-a-chip devices but also reduces the dependency on pharmaceutical R&D cycles for innovation and eventually results in sustained long-term market growth.

What are the Major Advances Changing the Organ-on-a-Chip Devices Market Today?

• Improved Microfluidic Engineering: Advanced microfluidic engineering is an important progressive step that is changing the market for organ-on-a-chip devices as it facilitates the very high-fidelity reproduction of the human organ microenvironments. The latest microfluidic systems are able to manage very accurately the flow of fluid, shear stress, levels of oxygen and gradients of nutrients, which are always the key to the viability of any tissue and imitating real physiological conditions. In addition to these advances, one can also follow the dynamic processes by using blood flow, breathing movements and mechanical strain that were hardly modelled in earlier static systems. As a consequence, cells act more human-like, and the data are more reliable to be used for the studies on the efficacy and toxicity of drugs. The improved microfluidic engineering has also eliminated the chances of errors in the experiment, has lessened the variations in the experiments, and has facilitated the long-term cell culture that, in turn, has made organ-on-a-chip systems more trustworthy, more widely applicable, and more adaptable for regular use in research on drugs and other new fields.

• Integration of Human Stem Cells and Organoids: The fusion of human stem cells and organoids is one of the most important changes that is taking place in the organ-on-a-chip devices market, as it greatly increases the biological relevance of these platforms. Usage of iPSCs, primary human cells, and patient-derived organoids in organ-on-a-chip systems allows for closely mimicking the human tissues in terms of structure, function, and disease. This combination of techniques allows for more accurate modeling of the transitioning of organs, genetic disorders, and the responses of drugs made for individual patients, which in turn, supports the move towards precision and personalized medicine. Furthermore, the chips made with stem cells and organoids let us study chronic toxicity, long-term drug exposure, and complex disease mechanisms that cannot be easily investigated by using the traditional cell cultures. Therefore, the advanced systems are becoming more and more attractive to the pharmaceutical industry, researchers, and doctors as they are capable of predicting human-relevant data and making animal testing unnecessary.

Category Wise Insights

By Product

Why Liver-on-a-Chip Lead the Market?

The liver-on-a-chip segment held the largest market share of over 35% in 2025. The expansion is propelled by its vital significance in the testing of drugs for safety and metabolism. The rise in revenue from this part of the business is robust, as the liver is the main organ that metabolizes and detoxifies drugs; furthermore, drug-induced liver injury (DILI) continues to be a major reason for the failure of clinical trials and the withdrawal of drugs from the market. More and more pharmaceutical and biotechnology companies are turning to liver-on-a-chip technology to obtain data on human-relevant hepatotoxicity and ADME early in the development process, which, in turn, helps to minimize the risk of costly failures in the late stage of the process and the use of animal models that are often unable to predict human liver responses.

The lung-on-a-chip segment is growing at the highest CAGR over the projected period. The development is mainly because of the increasing demand for human-like respiratory models in drug development, inhalation toxicology, and the research of diseases. The pulmonary system is very responsive to the environmental factors, viruses and bacteria carried in air, and drugs taken through inhalation; however, the conventional animal models and static cell cultures often do not provide an accurate representation of human lung physiology. Lung-on-a-chip has been the solution to the aforementioned problems by simulating important aspects like air-liquid interaction, breathing motion, and airflow and blood flow that are realistic, thus giving a more predictive evaluation of drug effectiveness and toxicity.

By End Use

Why Pharmaceutical & Biotechnology Companies Dominates the Organ-on-a-Chip Devices Market?

The pharmaceutical & biotechnology companies segment captures the largest market share of over 70% in 2025. because they are under the scrutiny of the regulators to make their drug development process less time-consuming and more effective with the elimination of late-stage clinical trial failures. The classical preclinical models, i.e., animal testing and 2D cell cultures, very often do not correctly predict human reactions, which results in the rejection of drug candidates and increasing research and development costs. Organ-on-a-chip devices present human-like, physiology-representative models that can better identify drug safety, efficacy, metabolism, and toxicity in the early phases, thus making them very appealing to pharmaceutical and biotechnological companies.

The academic & research institutes segment is expected to grow at the highest rate over the projected period. The increase in revenue is bolstered by the increase in the funding of public and private research. Such funds include government grants, international research programs, and industry-sponsored academic collaborations that are focused on finding alternatives to animal testing and precision medicine. Academic institutes frequently take the role of early adopters and validation hubs, buying OoC platforms, consumables, and customized devices, and at the same time, forming partnerships with technology providers to develop new models together.

Report Scope

Regional Analysis

How Big is the North America Organ-on-a-Chip Devices Market Size?

Its market size, in terms of North America organ-on-a-chip devices, is projected to be USD 68 million in 2025 with a growth of about USD 974 million in 2035 with a CAGR of 30.5% between 2026 and 2035.

Why did North America Dominate the Organ-on-a-Chip Devices Market in 2025?

In 2025, North America will dominate the global market with an estimated market share of 51%. Revenue growth in North America can be attributed to the active involvement of the regulators and also the regulatory policies that are most favorable including the ones that advocate the use of non-animal testing and the new approach methodologies. The collaboration between the Organs-on-Chip developers and the regulatory authorities and Contract Research Organizations has not only built up the confidence in the technology's value but also played a major role in integrating it into the preclinical workflow. Moreover, the combination of substantial public and private funding, venture capital investments, and the continuous technological innovations like advanced microfluidics, integrated sensors, and multi-organ systems are all contributing to the commercialization process. When looked at collectively, these factors put North America in the place of being the biggest and the fastest adopting regional market which in turn will lead to continuous revenue growth for the global organ-on-a-chip devices industry.

U.S. Organ-on-a-Chip Devices Market Trends

In the North American region, the US leads the industry expansion over the projected period. The market growth in the area is owing to the growing product launches. For instance, in June 2025, World Precision Instruments (WPI), a worldwide pioneer in transepithelial electrical resistance (TEER) technology, together with SynVivo, a company at the forefront of organ-on-chip (OOC) solutions, announced the launch of the EVOM™ Chip – a cutting-edge multiplex TEER system that has been specially created for the real-time, non-invasive observation of OOC platforms.

Why is Asia Pacific Experiencing the Fastest Growth in the Organ-on-a-Chip Devices Market?

Asia Pacific is growing at the highest CAGR over the analysis period. Strong government funding, partnerships between academia and industry, and the proliferation of research institutes and CROs throughout the Asia Pacific region are the main factors driving revenue growth. The majority of governments in the area are not only convincing the industry to switch from animal testing to alternatives but also providing the necessary funds for microfluidics, tissue engineering, and regenerative medicine research, which, in turn, supports the adoption of OoC. Besides, the presence of contract research and manufacturing organizations (CROs/CMOs) is growing and this makes it easy to offer organ-on-a-chip platforms for both domestic and international clients at a low cost. All these elements coupled with a huge patient base, a greater emphasis on precision medicine, and improved research infrastructure, are the ones that prop up the healthy revenue growth in the organ-on-a-chip devices market in the Asia Pacific.

China Organ-on-a-Chip Devices Market Trends

China is growing at the fastest rate over the projected period. The market growth is driven by the growing research and development. In a press release from July 2024, it was reported that Chinese scientists and biopharmaceutical companies are speeding up the research on organ-on-chip technology that imitates the lungs, livers, skin, and tumor spread of human beings. These devices which are about the size of a fingernail to a credit card are transparent and have a rubber-like texture, and inside them are 3D organ models made of cell cultures trapped in silicone and polymer materials.

Why is Europe is growing at a significant rate in the Organ-on-a-Chip Devices Market?

Europe holds the substantial market share over the projected period. This growth is facilitated by an infrastructural buildup which is anticipated to conduce the region's medical research opportunities to achieve a new threshold.

UK Organ-on-a-Chip Devices Market Trends

UK holds the dominant position in the Europe market. The growth is owing to the increasing funding and investment. In March 2024, Professor Hazel Screen's group of bioengineers at Queen Mary won a £7 million (USD 7.66 million) grant to create an EPSRC Centre for Doctoral Training (CDT) for the training of the next generation of scientists and bioengineers in OOC technologies.

Why is the Middle East & Africa Region is growing rapidly in the Organ-on-a-Chip Devices?

The MEA region is growing at a steady rate over the projected period. The ascendance of the market is credited to the rise in money allotted for healthcare infrastructure and biomedical research and also for life sciences innovations. The Middle East has long-term economic diversification plans as its main character, and these plans are leading to the formation of pharmaceutical and biotech ecosystems—particularly in the UAE, Saudi Arabia, and Israel. One of the factors contributing to this situation is a gradual change in the research tools employed, and among the most modern ones freely accepted are organ-on-a-chip devices that have found their way into drug discovery, toxicology studies, and disease modeling applications in academic institutions, government-funded research centers, and emerging biotech companies.

Saudi Arabia Organ-on-a-Chip Devices Market Trends

Saudi Arabia is growing at the highest CAGR during the forecast period. The growth is owing to the increasing government and academic funding in this sector.

Top Players in the Organ-on-a-Chip Devices Market and Their Offerings

• SynVivo Inc.

• BICO - THE BIO CONVERGENCE COMPANY

• Valo Health

• Nortis Inc.

• AxoSim

• MIMETAS B.V.

• CN Bio Innovations Ltd

• The Charles Stark Draper Laboratory, Inc.

• Emulate Inc.

• AlveoliX AG

• Merck KGaA

• Molecular Devices LLC

• F. Hoffmann-La Roche Ltd

• Vipragen

• Axion BioSystems, Inc

• Others

Key Developments

Organ-on-a-Chip Devices market has experienced considerable changes in the last two years as the market players are trying to diversify their technological aspects and develop product portfolios using strategic approaches.

• In October 2025, CN Bio recently made the announcement of the launch of its PhysioMimix® Core, which is the leading supplier of organ-on-a-chip (OOC) solutions to quicken drug discovery and development in laboratories. The new system, PhysioMimix Core, integrates the functions of CN Bio's already existing instruments and is the first OOC solution to provide certified performance across single-organ, multi-organ, and high-throughput configurations all in one microphysiological system (MPS). This move is part of the PhysioMimix brand, which represents the transfer of over a decade's worth of OOC knowledge. The result of such a development will be the gaining of important information about how drugs will behave in humans, thus taking away a lot of risks in the clinics and decreasing the usage of animal models significantly. The technology has already been acknowledged by the FDA of the U.S., and the top pharmaceutical companies all over the world are using it along with the support of a variety of validated protocols, consumables, and kits. (https://cn-bio.com/cn-bio-launches-all-in-one-organ-on-a-chip-system-physiomimix-core/)

These strategic measures have enabled the companies to reinforce their competitive positions, increase the product line, boost their technological competencies, and also seize growth opportunities in the fast-growing organ-on-a-chip devices market.

The Organ-on-a-Chip Devices Market is segmented as follows:

By Product

• Liver-on-a-Chip

• Lung-on-a-Chip

• Kidney-on-a-Chip

• Intestine-on-a-Chip

• Heart-on-a-Chip

• Others

By Application

• Drug Discovery

• Toxicology Research

• Disease Modeling/Physiological Model Development

• Stem Cell Research

• Tissue Regeneration and Regenerative Medicine

By End Use

• Academic & Research Institutes

• Pharmaceutical & Biotechnology Companies

• Contract Research Organization

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America